IL6 and congenital rubella syndrome: Early management of CRS mainly relied on the use of anti-IL-6 strategies, such as the FDA-approved monoclonal antibody tocilizumab, which targets the IL-6 receptor [50,55,56,57,58], and to a lesser extent the anti-IL6 antibody siltuximab [55,59].